-
2024-515300-39-00
4
2024-10-18
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
-
2024-516782-36-00
4
2024-10-15
metastatic or recurrent endometrial or ovarian carcinosarcoma
-
2024-514906-30-00
5
2024-10-14
"double diabetes"
-
2023-508539-30-00
4
2024-10-10
Refractory Focal Onset Epilepsy
-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional
-
2024-512921-10-00
1
2024-09-27
Advanced and/or Metastatic Solid Tumors
-
2024-511070-68-01
5
2024-09-24
Ampullary adenocarcinoma
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
-
2024-515118-42-00
11
2024-09-10
Colorectal cancer
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
-
2024-517204-11-00
4
2024-08-30
microsatellite stable (MSS) colorectal cancer with liver-dominant meta
-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2023-508435-31-00
1
2024-08-09
Advanced Solid Tumors, Advanced Breast Cancer
-
2022-502155-65-00
5
2024-07-30
Extra pulmonary sarcoidosis
-
2023-508260-30-01
5
2024-07-30
Patients with poor prognostic OVARian cancers based on the tumor prima
-
2024-515788-73-00
4
2024-07-30
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND
A HIGH IM
-
2024-514083-31-00
4
2024-07-26
squamous cell anal carcinoma
-
2023-508477-87-00
9
2024-07-24
Patients with localy advanced or metastatic non squamous non small cel
-
2022-502135-19-00
4
2024-07-18
Calcific Aortic Valve Stenosis
-
2023-505298-34-00
4
2024-07-18
Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc
-
2024-514107-34-00
4
2024-07-18
BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
-
2023-509571-16-00
3
2024-07-17
Lung Cancer
-
2023-509572-42-00
3
2024-07-17
Lung Cancer
-
2023-507641-29-00
4
2024-07-15
Locally Advanced or Metastatic Solid Tumors